30-April-2025
Asst. Prof. Paweena Chunharojrith, Siriraj Hospital
From DECLARE-TIMI 58 Dapagliflozin is proven to reduce the risk of hospitalization for heart failure and shown to reduce the risk of progression to nephropathy in patients with T2D and multiple CV risk factors or established CV disease vs placebo.

TH-13957

30-April-2025
Assoc. Prof. Pimjai Anthanont, Thammasat University Hospital

• Dapagliflozin demonstrated an improvement in UACR deterioration across all baseline UACR (including normo-albuminuria) and eGFR categories
• Early onset (at 6 months) and long-term (4 y)
• A reduction in renal-specific outcomes across all baseline UACR categories
• The results suggest a role for SGLT2i also in the primary prevention of diabetic kidney disease

TH-13958

30-April-2025
Anuttree Daorai, MD, Maharat Nakhon Ratchasima Hospital

• Data from the DECLARE–TIMI 58 study that establish the beneficial CV and renal effects of dapagliflozin in a robust number of elderly and very elderly participants
• The overall efficacy and safety of dapagliflozin were consistent regardless of age
  

TH-13959

30-April-2025
Assoc. Prof. Swangjit Sura-Amornkul, Vajira Hospital
In this multinational observational study, SGLT2i was associated with a lower risk of HF and CKD versus DPP4i in patients with type 2 diabetes otherwise free from both cardiovascular and renal disease.

TH-13960

30-April-2025
Ekgaluck Wanothayaroj, MD, Theptarin Hospital

• The benefits of GLP-1RA and SGLT2i on MACE are similar in patients with T2D
• Only GLP-1RA may reduce the risk of stroke
• The difference between these 2 drugs class are hospitalization for heart failure and kidney outcome
• SGLT2i has threefold benefit in reducing hHF and kidney outcomes when compare with GLP-1RA

TH-13961

30-April-2025
Capt. Pitak Pongnonthachai, MD, Somdech Phra Pinklao Hospital
From DAPA-HF

• Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes

TH-13962

30-April-2025
Chanikarn Kanaderm, MD, Central Chest Institute of Thailand (CCIT)
From DAPA-HF: Diabetes Prevention Analysis.

• This assessment from the DAPA-HF trial was a prespecified exploratory analysis
• Dapagliflozin decreased the incidence of T2D by 32% in 2,605 participants in the DAPA-HF trial compared to placebo in the participants who did not have T2D at baseline
• This effect was primarily driven by patients with baseline prediabetes
• Dapagliflozin is the first medication to demonstrate a reduction in new-onset T2D and mortality in a single trial

TH-13963

30-April-2025
Col. Waraporn Tiyanon, MD, Phramongkutklao Hospital
Analysis of the DAPA-HF trial by background therapy was conducted post hoc.

• Dapagliflozin consistently reduced the risk of worsening HF events and CV death when compared to placebo in patients with HFrEF, regardless of background therapy, with no significant randomized treatment-by-subgroup interaction
• Consistent benefit was seen regardless of background therapy dose and combination

TH-13964

30-April-2025
Gp. Capt. Somchodok Chakreeyarat, MD, Bhumibol Adulyadej Hospital

• In patients with T2DM with or at high atherosclerotic cardiovascular disease risk
• Dapagliflozin reduced risk of hospitalization for heart failure and renal outcomes regardless of baseline SBP, from the normal range to the most severely hypertensive
• No difference in adverse events of interest at any level of baseline SBP

TH-13965

30-April-2025
Asst. Prof. Worawut Roongsangmanoon, MD, HRH Princess Maha Chakri Sirindhorn Medical Center

• Patients with longer-duration HF were older and more comorbid, dapagliflozin was as well tolerated as placebo in patients with longer-duration HF
• Patients with longer-duration HF had more severe symptoms and higher rates of worsening HF and death. However, the benefits of dapagliflozin were consistent irrespective of HF duration, with greater absolute benefits obtained in patients with longer-duration HF

TH-13966

30-April-2025
Asst. Prof. Nipawan Waisayanand, MD, Maharaj Nakorn Chiang Mai Hospital
In the DECLARE–TIMI 58 trial.

• Patients with T2DM and higher BMI were at increased risk of HHF and AF/AFL
• Relative risk reductions in key CV outcomes with dapagliflozin were generally consistent across the range of BMI
• Absolute risk reduction in obesity-related outcomes; HHF and AF/AFL tended to be larger in obese patients with T2DM
• Relative and absolute risk reductions in renal-specific composite outcome with dapagliflozin were comparable across the range of BMI

TH-13967

30-April-2025
Artit Torpongpun, MD, Chonburi Hospital
SGLT2i can significantly reduce the risk of cardiovascular death or hospitalization for heart failure in patients with HFrEF regardless of DM status.

• SGLT2i and ARNI have similar effects on cardiovascular death or hospitalization for heart failure prevention
• The combined use of SGLT2i and ARNI results in a better cardiovascular protective effect

TH-13968

30-April-2025
Adj. Assoc. Prof. Sathit Niramitmahapanya, MD, Rajavithi Hospital
In the overall population, higher baseline HbA1c was associated with a higher risk of cardiovascular death or hospitalization for heart failure (HHF); major adverse cardiovascular events (MACE), including cardiovascular death, myocardial infarction, and ischemic stroke; and cardiorenal.

• Elevated HbA1c was associated with a greater increased risk for MACE and cardiorenal outcomes in patients with multiple risk factors (MRF) than in established ASCVD
• Compared with placebo, Dapagliflozin decreased the risk of cardiovascular death/HHF, HHF, and cardiorenal outcomes, with no heterogeneity by baseline HbA1c

TH-13969

30-April-2025
Ply Chichareon, MD, PhD, Songklanagarind Hospital

• TIMI biomarker-based risk score (hsTnT, NTproBNP, prior HF) for predicting hHF in T2DM at high atherosclerotic cardiovascular risk
• Excellent discrimination and well-calibrated in the external validation cohort
• Superior to TRS-HFDM (clinical-based risk score)
• Results highlight a role for comprehensive cardiovascular risk profiling in patients with T2DM and provide a potentially helpful decision support tool to clinicians who care for patients with T2DM

TH-13970

30-April-2025
Sirichai Cheewatanakornkul, MD, Songklanagarind Hospital
In this meta-analysis, patients with type 2 diabetes at high cardiovascular risk or with CKD, SGLT2 inhibitors reduced the risk of serious hyperkalemia (serum potassium ≥6.0 mmol/L) with no increased risk of hypokalemia.

• The lower risk of hyperkalemia with SGLT2 inhibitors was broadly consistent across a range of participant characteristics, including different levels of kidney function, albuminuria, history of heart failure, and concomitant use of diuretics

TH-13971

30-April-2025
Asst. Prof. Worapaka Manosroi, MD, Maharaj Nakorn Chiang Mai Hospital
Use of SGLT-2 inhibitors combined with metformin for diabetic patients during Ramadan fasting is

• Effective
• Safe and well-tolerated
• Reduced hypoglycemic events (symptomatic and documented)

TH-13972

30-April-2025
Nattakarn Suwansaksri, MD, Khon Kaen Hospital
Patients with T2DM and previous MI are at high risk of MACE and cardiovascular death/hHF.

• Dapagliflozin appears to robustly reduce the risk of both events in these patients
• Future studies should aim to confirm the large clinical benefits with SGLT2i that we observed in patients with previous MI

TH-13973

30-April-2025
Assoc. Prof. Adisai Buakhamsri, MD, Thammasat University Hospital
Presence of ASCVD in T2DM increases risk of heart failure hospitalization.

• Currently, clinical guidelines from professional societies have recommended SGLT2i inhibitor as a preferred agent in patients with T2DM who have elevated cardiovascular risk
• For T2DM patients without ASCVD, Dapagliflozin may offer a more favorable effect on HHF, compared to empagliflozin in this retrospective cohort

TH-13974

30-April-2025
Wanut Chaitree, MD, Medical Development Clinic

• Results showed beneficial effects regarding reduction of hepatic lipid accumulation in non-insulin-dependent T2DM and NAFLD following treatment with dapagliflozin for 12 weeks
• These benefits occurred together with improvement in glycemic control, weight loss promotion, decrease in body fat, improvement of glycemic profiles and decreased liver alanine aminotransferase
• The adipocytokines associated with NAFLD were not significantly different following dapagliflozin treatment when compared with placebo
• There were no significant adverse events reported in this study

TH-13975

30-April-2025
Oraphan Larpnikornkul, MD, Banphaeo General Hospital (BGH)
The main finding of this analysis was that Dapagliflozin reduced the risk of the composite outcome of an investigator-reported serious ventricular arrhythmia, resuscitated cardiac arrest, or sudden death in patients with HFrEF.
 

TH-13976